Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Premiere Research Institute

Neither a doctor nor a teaching hospital

Research payments

$4,662,175

430 payments

Through program year 2025, Premiere Research Institute is reported as receiving $4,662,175 in research payments, across 430 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $509,092 12
2024 Research $328,322 3
2023 Research $723,881 19
2022 Research $141,826 8
2021 Research $673,906 46
2020 Research $1,444,396 81
2019 Research $840,753 261

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,037,203 20 payments
  2. Eisai Inc. $1,775,763 276 payments
  3. Allergan Inc. $359,175 54 payments
  4. Amgen Inc. $182,599 44 payments
  5. E.R. Squibb & Sons, L.L.C. $109,426 2 payments
  6. AbbVie, Inc. $99,425 19 payments
  7. Supernus Pharmaceuticals, Inc. $34,769 3 payments
  8. Merz Pharmaceuticals, LLC $31,700 4 payments
  9. Teva Pharmaceuticals USA, Inc. $31,608 7 payments
  10. Biogen, Inc. $506 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $1,476,871 7 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,250,789 42 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $524,975 234 payments
  4. A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy $342,486 6 payments
  5. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $146,105 20 payments
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $94,426 1 payment
  7. A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 MG Subcutaneous Ofatumumab Injected By Pre-Filled Syringe Or Autoinjector in Adult RMS Patients $91,990 1 payment
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $90,204 9 payments
  9. A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light $82,626 2 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $66,704 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record